Merck Serono to build production facility in China

11/18/2013 | Genetic Engineering & Biotechnology News

Merck Serono plans to invest $107 million to construct a 430,556-square-foot biopharmaceutical manufacturing site in Shanghai. The facility will be the company's second-largest in the world and will manufacture Merck's leading heart- and metabolic-disease treatments including diabetes drug Glucophage, thyroid drug Euthyrox and heart treatment Concor. Construction is set to begin next year and be finished in 2016.

View Full Article in:

Genetic Engineering & Biotechnology News

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Pharmacy Care Manager
National Association of Chain Drug Stores
Arlington, VA
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC
Sr. Principal OptoMechanical Engineer - 14000008M2
San Jose, CA
Director, Compliance - Health Plan Privacy & Security
Kaiser Permanente
Oakland, CA
Regional Director, Southeastern Region - State Affairs
America's Health Insurance Plans (AHIP)
Washington, DC